LNSR
$6.89
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System.
Recent News
BYND And LNSR Set The Tone Tuesday
Earnings concerns and deal collapse drive moves
Fed Kicks Off Policy Meeting as US Equity Futures Tread Water Pre-Bell
US equity futures were little changed ahead of Tuesday's opening bell as traders stayed on the sidel
Alcon abandons effort to purchase LENSAR after FTC scrutiny
The Federal Trade Commission said the transaction had threatened to raise prices and stifle innovation for cataract laser eye surgery systems.
Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit
Stock index futures are experiencing a notable surge, reflecting renewed investor optimism, primarily driven by reports suggesting that the U.S. administration may reduce the scope of proposed tariffs, potentially excluding certain sectors. Such developments have bolstered market sentiment, leading to premarket gains across major indices. In the commodities market, oil prices have experienced a slight decline as investors closely monitor ongoing ceasefire talks between Russia and Ukraine. The